|
INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt. |
|
Cornelis Martinus van Tilburg |
Consulting or Advisory Role - Bayer; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck; Novartis; Roche |
Consulting or Advisory Role - Bayer (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst) |
Research Funding - Bayer (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Diagnosing and treating IDH1-mutant cancers; Treating cancers with AHR antagonists; Treating H3.3K27M-mutant cancers |
Travel, Accommodations, Expenses - Merck; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Abbvie/Abbott |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Gnana Prakash Balasubramanian |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |